Harness Integrated Toxicology for Faster Data-Driven Decisions
Effectively make your crucial go/no-go decisions with the integrated toxicology services offered at our Kansas site. Accelerate your studies with four-day study initiation, instantly access your study data and 10-day post-study reports for non-GLP PK, dose range finding, and toxicology with our specialized technical staff. Our comprehensive resources will allow you to expedite your data retrieval and mitigate risks when preparing your investigational new drug programs.
42,123
reports delivered in 2022
1,500
IND programs supported last year
100
years of combined scientific experience
324,932
digital pathology slides scanned in a year
Integrated Toxicology Capabilities
You can benefit from our expanded integrated toxicology strategy by providing:
- Follow-on work to Discovery studies
- Enhancements to CRADL through expanded expertise and offerings
- Flexibility for in vivo lead optimization studies within Safety Assessment
You can make fast, confident decisions on the potential of drug candidate to move forward through development with our tailored dose escalation study design.
We offer a consistent study design and a wide range of capabilities including:
- Rapid study starts
- Complete evaluations, including enhanced formulations, decreased blood volume requirements in clinical pathology, microsampling in bioanalytical chemistry, biomarkers, automation that accelerates key steps in histology, and high throughput whole slide image scanners in digital pathology
- Data to make critical go/no-go decisions
Unlock Faster, Smarter Toxicology Decisions
Learn how real-time toxicology data and digital pathology drive accelerated decision-making and reduce costly delays.
Watch the Webinar
Quality in Kansas Starts with Experienced Staff: Meet the Team
Subject matter experts across a multitude of our global sites were consulted to create a team of highly skilled, dedicated functional leads and support staff to drive quality from study start through expedited data delivery.
Brian Roche, PhD
General Manager at Charles River Kansas
Dr. Brian Roche, General Manager at Charles River’s Kansas site, has more than 20 years’ experience in preclinical drug development with a focus on research from early pharmacology through GLP safety pharmacology studies. In his previous role as the Executive Director of Global Safety Pharmacology, he provided scientific expertise and leadership on behalf of the Global Safety Pharmacology portfolio, including strategy development and best practice alignment across sites.
Dr. Roche received his doctorate in cardiovascular physiology from Ohio State University under the guidance of Dr. Robert Hamlin and he furthered his education at Ohio State as a postdoctoral research fellow. He is an active member of the international scientific community and served as the president of the Safety Pharmacology Society in 2021. Dr. Roche, who is dual-boarded as a Toxicologist (DABT) and Safety Pharmacologist (DSP), published 24 peer-reviewed scientific papers and a chapter book.
Kate Voss
Associate Director Toxicology, Charles River Kansas
Kate Voss is the Associate Director of Toxicology at Charles River, Kansas. With a robust tenure exceeding 17 years at Charles River, she has distinguished herself through her leadership in numerous pivotal studies. As a Study director, she has spearheaded research across a spectrum of disciplines including Chemistry, Toxicokinetics, Pharmacology, and Biochemistry. Her strategic vision and managerial acumen have been instrumental in her role as a program manager, where she seamlessly integrated scientific inquiry with programmatic execution.
Partner with us and access a diverse range of client-centric services, spanning dose formulation, non-GLP toxicology, bioanalytical support, necropsy, histology, clinical pathology, digital pathology, and flexible but comprehensive report preparation, all tailored to meet your specific needs. Reach out to us now to harness our expertise and propel your drug development initiatives forward.